Newer Biomarkers Slightly Improve Prediction of Progression to Renal Replacement Therapy in CKD Patients – CanPREDICT Study Outcomes

Adeera Levin1, MD, Ognjenka Djurdjev2, Claudio Rigatto3, MD, Francois Madore4, MD, Brendan J. Barrett5, MD, Norman Muirhead6, MD, Myles S. Wolf7, MD

1University of British Columbia, Vancouver, BC, Canada, 2BC Provincial Renal Agency, Vancouver, BC, Canada, 3University of Manitoba, Winnipeg, MB, Canada, 4University of Montréal, Montreal, QC, Canada, 5Memorial University of Newfoundland, St. John’s, NL, Canada, 6University of Western Ontario, London, ON, Canada, 7University of Miami Miller School of Medicine, Miami, FL, USA

BACKGROUND: Patients with chronic kidney disease (CKD) experience variable progression of kidney disease (KD). Better prediction models are needed. To assess if newer biomarkers (NBM), alone or as a panel, improve risk prediction of renal replacement therapy (RRT), over and above conventional clinical, demographic and laboratory predictors.

METHODS: Pan-Canadian prospective cohort study of 2544 referred CKD patients, from 25 centres. NBM tests at baseline included asymmetric dimethylarginine (ADMA), high sensitivity C-reactive protein (hsCRP), interleukin 6, pro-brain natriuretic peptide (NTproBNP), troponin I, transforming growth factor β1, cystatin C and fibroblast growth factor (FGF23). Outcome: dialysis or transplantation (RRT) within 3 years. We compared discrimination (C statistic) and classification (net reclassification index (NRI)) of proportional hazards models based on conventional vs. combination of conventional and NBM predictors.

RESULTS: Mean age of the cohort is 68yrs; median eGFR was 28ml/min/1.73m2 (20% <20ml/min, 38% 20-29ml/min and 41% 30-45ml/min); 62% were male. 14.4% patients initiated RRT during the 3-year follow-up. Models based on base, base+NBM and 'best' predictors are presented in the following figure:
CONCLUSIONS: This is the first analysis of CKD cohort progression that includes NBM as a panel. Although NBMs are independent predictors of RRT progression, addition of the panel of NBMs to models based on conventional clinical, demographic and laboratory predictors results in only modest improvement of RRT risk prediction.